Cowboyd - Here is DNAP's listing of their drug/drug classifier pipeline from the recent S2 filing on the new joint venture with Biofrontera...just in case you may have missed this.
DNAP's pipeline is exciting and quite extensive across many diseases.... While it's still a time-game, it's possible that DNAP's own classifiers could be ready first, including their Acenome product, since they've had these in the pipeline for a while.
Plus, DNAP has been working with Moffitt since Nov 03, and considering Moffitt/DNAP's cancer research areas only involve drug classifiers (not drug development), we could see action on one or more of these areas as well.
The drug development and clinical trials of course will be more time-demanding, tho a big part of the puzzle is DNAP's ADMIXMAP technology that will help accelerate this process. As Tony clearly states..."drugs are where the $millions are..."
You mentioned that "With all that said I continue to believe this little company has more going for it on the potential side than any other I am aware of."
I totally agree...I have found no other biotech that even comes close to DNAP's potential...and this list of DNAP's pipeline projects that have $billion dollar markets strongly reinforces that for me....
Plus...the fact that DNAP is...now officially a "drug company"... Exciting...
Good to hear from you again... Enjoy the list of "our" pipeline possibilities...
From the SEC S2 filing on DNAP/Biofrontera Joint Ventures
2.1 DNAPrint and Biofrontera both own technologies that provide an ideal fit to discover new drugs and develop them to market. To make optimal use of the combined resources, they have agreed to set out Joint Ventures with the objective to develop medications for sale. The parties will openly exchange confidential information about their respective technologies, and agree to undertake commercially reasonable practices to within 90 days or sooner enter into a definitive agreement upon the formation of mutually beneficial Joint Ventures for the joint development of selected projects.
Each Joint Venture shall be formed under a separate agreement, the general principles of which are set out in Clause 3.
The parties or their affiliated companies have the following compounds and technologies under development:
Biofontera's projects at the preclinical research stage include:
Cathepsin inhibitors
Inhibitors for protease activated receptors
Inhibitors for sphingomyelinase
Kinase inhibitors
Biofrontera's projects at the preclinical development stage include:
- 5-HT2B receptor inhibitor for migraine prophylaxis
Biofrontera's projects at the clinical development stage include:
Histidine decarboxylase inhibitor (Phase II)
Skin cancer drug (Phase II, inlicensing deal curr.closed)
DNAPrint's projects include:
Ovanome - Taxol/Carboplatin efficacy
Statnome - Lipitor, Zocor, efficacy
Statnome Muscle - Lipitor, Zocor adverse myalgia response
Acenome - Enalapril, Lisinopril efficacy
Acenome Muscle - Enalapril, Lisinopril adverse cough
Immunosuppressants - Sirolimus, Tacrolimus, Mycophenolate
mofetil efficacy in transplant patients
Moffitt/DNAP projects include:
1) Response of Metastatic Colorectal Cancer to Irinotecan/Capecitabine (Xeliri) and Oxaliplatin/Capecitabine (Xelox)
2) Melphalan and Topotecan (MT) efficacy for treatment of Multiple Myeloma
3) Cyclophosphamide efficacy
4) Organistron adverse events - post operative nausea and vomiting
5) Esophageal malignancy chemotherapy response - standard FDA treatment
-----------
Wonder what other surprise projects DNAP has for us on the back burners...lol!
God's Speed To DNAP's Vision and To All DNAP Investors
Robert